GGrantIndex
← Leaderboards

Yvonne J Rosenberg

Procell Corporation

$9,253,501
Attributed
$9,253,501
Total exposure
11
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.4M · FY200721
$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21

Funding mix

By agency

NIH$9,253,501 · 11

By mechanism

R44$6,305,700 · 3
R43$1,496,034 · 7
U44$1,451,767 · 1

Top collaborators

No co-investigators on record.

Others in their field

Top investigators on “Response

Research focus

ResponseProductionExhibitsMacacaSmall Business Innovation Research GrantRecombinantsGrantPlantsAntibodiesPreventDrug KineticsEnzymesOrganophosphatesCessation Of LifeNeurotoxicityToxic EffectBloodDoseInsecticidesPublic Health RelevanceInjection Of Therapeutic AgentNeutralizing AntibodyBaseInnovation

Grant awards (19)

Development of a handheld PEST-pen device for the rapid detection of organophosphate insecticides on food and clothing$515,084
R44 · FY2021 · ES · contact PI
Development of a handheld PEST-pen device for the rapid detection of organophosphate insecticides on food and clothing$705,843
R44 · FY2020 · ES · contact PI
Zwitterionic oxime (RS194B) to reverse advanced symptoms and lethality of organophosphate pesticide exposure$224,858
R43 · FY2018 · NS · contact PI
Development of a handheld PEST-pen device for the rapid detection of organophosphate insecticides on food and clothing$149,980
R43 · FY2018 · ES · contact PI
Plant-derived HIV neutralizing mAbs for passive immunotherapy in newborn macaques$1,000,000
R44 · FY2017 · AI · contact PI
Plant-derived HIV neutralizing mAbs for passive immunotherapy in newborn macaques$1,000,000
R44 · FY2016 · AI · contact PI
Augmentation of HIV Env vaccine efficacy by DC targeting$224,813
R43 · FY2015 · AI · contact PI
Efficacy and Safety of an Aerosolized Recombinant Butyrylcholinesterase Pretreatm$5,000
R44 · FY2015 · NS · contact PI
Efficacy and Safety of an Aerosolized Recombinant Butyrylcholinesterase Pretreatm$858,920
R44 · FY2014 · NS · contact PI
Efficacy and Safety of an Aerosolized Recombinant Butyrylcholinesterase Pretreatm$753,417
R44 · FY2013 · NS · contact PI
Passive immunotherapy using plant-derived broadly HIV-1 neutralizing MAbs to prev$741,390
R44 · FY2012 · AI · contact PI
Aerosol Delivery of a Recombinant Butyrylcholinesterase "BioShield" to Protect Ag$618,077
U44 · FY2012 · NS · contact PI
Passive immunotherapy using plant-derived broadly HIV-1 neutralizing MAbs to prev$726,046
R44 · FY2011 · AI · contact PI
Aerosol Delivery of a Recombinant Butyrylcholinesterase "BioShield" to Protect Ag$545,727
U44 · FY2010 · NS · contact PI
Aerosol Delivery of a Recombinant Butyrylcholinesterase "BioShield" to Protect Ag$287,963
U44 · FY2009 · NS · contact PI
Passive immunotherapy using plant-derived broadly HIV-1 neutralizing MAbs to prev$256,501
R43 · FY2009 · AI · contact PI
Induction of 2G12 neutralizing antibody by plant-derived HIVgp145$222,753
R43 · FY2007 · AI · contact PI
A Plant-Derived Recombinant Bioscavenger to Prevent Insecticide Neurotoxicity$169,584
R43 · FY2007 · NS · contact PI
Immunogenicity of plant-expressed p55 Gag and gp120$247,545
R43 · FY2003 · AI